Philip Morris Product Evaluation Scientific Advisory Board

The role of this Scientific Advisory Board (SAB) is, upon request of Philip Morris USA (Philip Morris), to assess the adequacy and quality of investigations related to acceptability (i.e. a comparison to existing cigarette products) and harm reduction (i.e. the potential for a meaningful reduction in smoking-related disease) of newly developed products for adult smokers. The SAB's assessment will contribute to the validity of the data relied upon by Philip Morris to evaluate the characteristics of new products for adult smokers. Such characteristics include chemical composition, biological activity in model systems, and exposure and health effects in humans. As part of this work, the SAB may be requested to review the use of assays or procedures that deal principally with the acceptability of materials and apply to both reduced harm products and standard products alike. Additionally, the SAB may be requested to comment on the scientific aspects of studies designed principally to answer fundamental questions about smoking and health, such as a comprehensive evaluation of human exposure to smoke constituents.

To fulfill this role, the SAB will:

- review and comment on Philip Morris acceptability and harm reduction testing guidelines for the comprehensive representation of predominant standards and published concepts which are pertinent and appropriate to each respective guideline, and for accuracy and scientific soundness in applying these concepts to the evaluation of products for adult smokers;
- review and comment on study designs;
- assess protocols and facilities as needed;
- periodically assess the progress and quality of the studies data by appropriate means, including on-site visits as may be useful;
- review in-progress and final test data.

In the course of its work, the SAB will receive:

- Briefings on the characteristics of products to be assessed including the chemical and physical performance properties of the new products so that an adequate review of the proposed evaluations can be conducted.

- Briefings on proposed Philip Morris study designs and/or protocols for the determination of chemical composition and biological activity, and for human exposure and health effects studies.

- Access to testing facilities, clinical sites, analytical laboratories and other related facilities, and to all relevant test data necessary to fulfill its role.

PM3001338434

Source: https://www.industrydocuments.ucsf.edu/docs/qqpj0001

The SAB will provide to Philip Morris:

- written reviews and recommendations on Philip Morris's acceptability and harm reduction guidelines
- periodic status reports of its reviews of study designs and, as considered necessary, protocols, on-site visits of facilities, and data;
- final written reports on the scientific quality and quantity of the work performed and the validity of the data, and;
- comments on the validity of the interpretation of study results and conclusions.

The Senior Management of Philip Morris Research, Development and Engineering will receive copies of written communications from the SAB and are invited to attend all SAB Meetings.

At least the following disciplines should be represented by members of the SAB:

- Toxicology/Pharmacology
- Analytical Chemistry
- Pathology
- Clinical pharmacology
- Epidemiology / Biostatistics

The SAB may recommend the use of experts in other fields (e.g. biochemistry, molecular biology or pulmonology) on a temporary basis in order to better address specific topics.

A consultant with previous experience at Philip Morris will be made available to the SAB as a subject matter expert, to assist the SAB in its understanding of cigarettes in areas such as the chemistry and toxicology of smoke.

Secretarial and technical support can be provided by Philip Morris to the SAB to assist the SAB in fulfilling its role.

PM3001338435

Source: https://www.industrydocuments.ucsf.edu/docs/qqpj0001